MR308

DRUG2 trials

Sponsors

Mundipharma Research GmbH & Co KG

Conditions

Acute Pain

Phase 3

Efficacy and Safety in a Randomised Acute Pain Study of MR308 (Tramadol/Celecoxib).

CompletedNCT02982161

Mundipharma Research GmbH & Co KGAcute Pain

Start: 2016-12-28End: 2018-01-04Updated: 2018-05-29

Efficacy and Safety in a Randomised Acute Pain Study of MR308: STARDOM2.

CompletedNCT03062644

Mundipharma Research GmbH & Co KGAcute Pain

Start: 2017-04-05End: 2018-06-29Updated: 2018-09-20

Related Papers

Safety of Co-Crystal of Tramadol-Celecoxib (CTC) in Patients with Acute Moderate-to-Severe Pain: Pooled Analysis of Three Phase 3 Randomized Trials

Pain and Therapy2024-09-242 citations

Efficacy of Co-Crystal of Tramadol-Celecoxib (CTC) in Patients with Acute Moderate-to-Severe Pain: A Pooled Analysis of Data from Two Phase 3 Randomized Clinical Trials.

2024-06-141 citations

Co-crystal of Tramadol-Celecoxib Versus Tramadol or Placebo for Acute Moderate-to-Severe Pain After Oral Surgery: Randomized, Double-Blind, Phase 3 Trial (STARDOM1)

Advances in Therapy2024-01-0610 citations

Efficacy and safety of co‐crystal of tramadol‐celecoxib (<scp>CTC</scp>) in acute moderate‐to‐severe pain after abdominal hysterectomy: A randomized, double‐blind, phase 3 trial (<scp>STARDOM2</scp>)

European Journal of Pain2022-08-1718 citations

Pharmacokinetics of Tramadol and Celecoxib in Japanese and Caucasian Subjects Following Administration of Co-Crystal of Tramadol-Celecoxib (CTC): A Randomised, Open-Label Study.

2019-02-013 citations